Thr357
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr357  -  HSF1 (human)

Site Information
DARGHtDtEGRPPsP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15420204
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 7 , 8 , 9 , 10 , 11 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , leukemia ( 8 ) , acute myelogenous leukemia ( 8 ) , lung cancer ( 4 , 5 , 7 ) , non-small cell lung cancer ( 4 , 5 , 7 ) , non-small cell lung adenocarcinoma ( 4 , 5 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:
293 (epithelial) ( 10 , 11 ) , breast ( 2 ) , Cal-12T (pulmonary) ( 5 ) , Calu 6 (pulmonary) ( 7 ) , DMS153 (pulmonary) ( 4 ) , HCC1359 (pulmonary) ( 7 ) , HCC366 (pulmonary) ( 7 ) , HCC4006 (pulmonary) ( 7 ) , HCC44 (pulmonary) ( 5 ) , HCC78 (pulmonary) ( 7 ) , HCC827 (pulmonary) ( 7 ) , HeLa (cervical) ( 1 ) , Jurkat (T lymphocyte) ( 9 ) , KG-1 (myeloid) ( 8 ) , LCLC-103H (pulmonary) ( 7 ) , LOU-NH91 (squamous) ( 7 ) , lung ( 4 , 5 ) , NCI-H1437 (pulmonary) ( 4 , 5 ) , NCI-H157 (pulmonary) ( 7 ) , NCI-H1648 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 5 , 7 ) , NCI-H2073 (pulmonary) ( 4 ) , NCI-H209 (pulmonary) ( 4 ) , NCI-H2405 (pulmonary) ( 5 ) , NCI-H460 (pulmonary) ( 7 ) , NCI-H838 (pulmonary) ( 4 ) , WM239A (epidermal) ( 3 )

References 

1

Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296
27281782   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

7

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

8

Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56
22115753   Curated Info

9

Possemato A (2010) CST Curation Set: 10300; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-Thr-Pro Motif Antibody (polyAB) Cat#: 3003, PTMScan(R) Phospho-Thr-Pro Motif (T*P) Immunoaffinity Beads Cat#: 1996
Curated Info

10

Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info

11

Guo A (2010) CST Curation Set: 9974; Year: 2010; Biosample/Treatment: cell line, 293/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368
Curated Info